胰高血糖素样肽1受体激动剂治疗多囊卵巢综合症的效果分析

目的 探讨胰高血糖素样肽1受体激动剂对多囊卵巢综合症的临床疗效.方法 收集2015年3月至2016年3月入院的72例多囊卵巢综合症患者,随机分为对照组与实验组.对照组二甲双胍+达英35联合治疗,实验组二甲双胍+胰高血糖素样肽1受体激动剂治疗,比较两组治疗前后相关临床指标与临床事件发生率.结果 治疗后,实验组空腹胰岛素(9.55±1.47)μU/ml]、餐后2h胰岛素(56.83±9.54)μU/ml]、总胆固醇(1.17±0.34) mmol/L]、低密度脂蛋白(2.24±0.21) mmol/L]、促黄体生成素(6.61±0.37) mmol/L]、垂体分泌卵泡刺激素(1.39±0.44) mmol/L]、睾丸酮(0.13±0.06)mmol/L]与垂体泌乳素水平(52.04±13.58 mmol/L)]均显著低于对照组(12.33±2.03)μU/ml、(80.64±10.78)μU/ml、(1.43±0.31)mmol/L、(2.55±0.26) mmol/L、(7.09±0.43) mmol/L、(3.05±0.71)mmol/L、(0.39±0.16) mmol/L、(80.16±11.48) mmol/L],差异有统计学意义(均P＜0.01);实验组排卵率(75.00％)与妊娠率(44.44％)明显高于对照组(50.00％、19.44％),差异有统计学意义(均P＜0.05).结论 胰高血糖素样肽l受体激动剂治疗多囊卵巢综合症临床效果显著,具有借鉴意义.

Glucagon-like peptide-1 receptor agonist for polycystic ovary syndrome

Objective To investigate the clinical efficacy of glucagon-like peptide-1 receptor agonist for polycystic ovary syndrome (PCOS).Methods 72 patients with PCOS admitted into our hospital from March,2015 to March,2016 were randomly divided into a control group and an experimental group.The control group were treated with metformin and dalben 35 and the experimental group with metformin and glucagon-like peptide-1 receptor agonist.The clinical indicators and clinical events before and after the treatment were compared between these groups.Results The levels of fasting insulin (9.55 ± 1.47) μU/ml],postprandial insulin (56.83 ±9.54) μU/ml],total cholesterol (1.17 ± 0.34) mmol/L],low density lipoprotein (2.24 ± 0.21) mmol/L],luteinizing hormone (6.61 ± 0.37) mmol/L],testosterone (0.13±0.06) mmol/L],and pituitary prolactin (52.04 ± 13.58)mmol/L] in the experimental group were significantly lower than those in the control group (12.33±2.03) μU/ml,(80.64±10.78) μU/ml,(1.43±0.31) mmol/L,(2.55±0.26) mmol/L,(7.09±0.43) mmol/L,(3.05±0.71)mmol/L,(0.39±0.16) mmol/L,and (80.16±11.48) mmol/L],with statistical differences (all P ＜ 0.01).The ovulation rate and the pregnancy rate were 75.00％ and 44.44％ in the experimental group and were 50.00％ and 19.44％ in the control group,with statistical differences (all P ＜ 0.05).Conclusion Glucagon-like peptide-1 receptor agonist for polycystic ovary syndrome is obviously effective,so it is of reference.